Combination therapy with anti-CTLA4 and anti-PD1 leads to distinct immunologic changes in-vivo

Combination therapy concurrently targeting PD1 and CTLA4 immune checkpoints leads to remarkable anti-tumor effects. While both PD1 and CTLA4 dampen the T cell activation, the in vivo effects of these drugs in humans remain to be clearly defined. In order to better understand biologic effects of ther...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Immunol
Hauptverfasser: Das, Rituparna, Verma, Rakesh, Sznol, Mario, Boddupalli, Chandra Sekhar, Gettinger, Scott N., Kluger, Harriet, Callahan, Margaret, Wolchok, Jedd D, Halaban, Ruth, Dhodapkar, Madhav V., Dhodapkar, Kavita M.
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2014
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4380504/
https://ncbi.nlm.nih.gov/pubmed/25539810
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4049/jimmunol.1401686
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge